EGFR and non-small cell lung carcinoma: Amivantamab received FDA approval in May 2021116 based on the CHRYSALIS trial (NCT02609776), which evaluated the combination of amivantamab and lazertinib in EGFR-mutant NSCLC patients who had progressed on third-generation TKI (tyrosine kinase inhibitor) monotherapy but were chemotherapy naive.117